We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > Rozlytrek

News List

FDA Approves Rozlytrek (entrectinib) for People With ROS1-Positive, Metastatic Non-Small Cell Lung Cancer and NTRK Gene Fusion-Positive Solid Tumors drugs
August 16, 2019
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.S. Food and Drug Administration (FDA) has approved Rozlytrek (entrectinib) for the treatment of adults with ROS1-positive...
Japan first to approve Roche’s tumour-agnostic medicine Rozlytrek pharmaceutical-technology
June 20, 2019
Japan approves Roche’s personalised medicine Rozlytrek. Credit: © 2015 F. Hoffmann-La Roche.
Japan becomes the first country to approve Roche's personalised medicine Rozlytrek worldpharmanews
June 20, 2019
Japan becomes the first country to approve Roche's personalised medicine Rozlytrek.
Japan the first to approve Roche’s personalised medicine Rozlytrek biospectrumasia
June 19, 2019
First tumour-agnostic medicine approved in Japan for adult and paediatric patients with NTRK fusion-positive advanced recurrent solid tumours
Japan First to Approve Roche’s Rozlytrek contractpharma
June 19, 2019
A tumor-agnostic medicine for treatment of adult and pediatric patients with NTRK fusion-positive advanced recurrent solid tumors/

Previous page 1 2 Next page